Helius Medical Technologies (NASDAQ:HSDT) Raised to Hold at Wall Street Zen

Posted by Renee Jackson on Aug 19th, 2025

Wall Street Zen upgraded shares of Helius Medical Technologies (NASDAQ:HSDT – Free Report) from a sell rating to a hold rating in a research note released on Saturday.

Helius Medical Technologies Stock Performance

NASDAQ HSDT opened at $6.43 on Friday. The stock has a market cap of $64,300.00, a P/E ratio of 0.00 and a beta of 0.73. Helius Medical Technologies has a fifty-two week low of $5.37 and a fifty-two week high of $1,200.00. The stock has a 50 day simple moving average of $11.85 and a two-hundred day simple moving average of $186.10.

Helius Medical Technologies (NASDAQ:HSDT – Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($79.73) EPS for the quarter, topping analysts’ consensus estimates of ($128.50) by $48.77. The company had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.11 million. Helius Medical Technologies had a negative return on equity of 1,040.32% and a negative net margin of 7,215.25%.

Hedge Funds Weigh In On Helius Medical Technologies

A hedge fund recently bought a new stake in Helius Medical Technologies stock. Wealthspire Advisors LLC acquired a new stake in shares of Helius Medical Technologies, Inc. (NASDAQ:HSDT – Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 300,000 shares of the company’s stock, valued at approximately $55,000. Wealthspire Advisors LLC owned approximately 3,000.00% of Helius Medical Technologies as of its most recent filing with the SEC. Hedge funds and other institutional investors own 18.63% of the company’s stock.

About Helius Medical Technologies

(Get Free Report)

Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.